Artelo Biosciences Inc Total Assets
Artelo Biosciences Inc total assets. Based on the latest financial reports, Artelo Biosciences Inc (ARTL) holds total assets worth $6.46 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Artelo Biosciences Inc for the company's overall valuation and market capitalisation.
Total Assets of Artelo Biosciences Inc (2014–2025)
Total assets of Artelo Biosciences Inc from 2014 to 2025. This chart illustrates how Artelo Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See ARTL share price today for real-time trading data and today's change.
Artelo Biosciences Inc - Asset Composition Analysis
Artelo Biosciences Inc Total Assets Breakdown (December 2025)
Artelo Biosciences Inc total assets breakdown as of December 2025. Artelo Biosciences Inc's total assets of $6.46 Million consist of 24.8% current assets and 75.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.04 Million | 72.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Artelo Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Artelo Biosciences Inc (ARTL) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Artelo Biosciences Inc's current assets represent 24.8% of total assets in 2025, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 21.4% of total assets in 2025, down from 100.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 72.8% of total assets.
Artelo Biosciences Inc Competitors by Total Assets
Key competitors of Artelo Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Artelo Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.00 | 0.39 | 19.61 |
| Quick Ratio | 3.00 | 0.39 | 19.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.92 Million | $-3.48 Million | $9.79 Million |
Artelo Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Artelo Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.47 |
| Asset Growth Rate (YoY) | -40.4% |
| Total Assets | $2.80 Million |
| Market Capitalization | $1.31 Million USD |
Valuation Analysis
Below Book Valuation: The market values Artelo Biosciences Inc's assets below their book value (0.47x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Artelo Biosciences Inc's assets decreased by 40.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Artelo Biosciences Inc (2014–2025)
The table below shows the annual total assets of Artelo Biosciences Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.80 Million | -40.38% |
| 2024-12-31 | $4.70 Million | -63.98% |
| 2023-12-31 | $13.04 Million | -36.14% |
| 2022-12-31 | $20.42 Million | +61.65% |
| 2021-12-31 | $12.63 Million | +188.73% |
| 2020-12-31 | $4.38 Million | -32.50% |
| 2019-12-31 | $6.48 Million | +1532.94% |
| 2018-12-31 | $397.00K | -30.87% |
| 2017-12-31 | $574.27K | +15896.52% |
| 2016-12-31 | $3.59K | -78.92% |
| 2015-12-31 | $17.03K | +15.60% |
| 2014-12-31 | $14.73K | -- |
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a coc… Read more